Paolo Tarantino: How do you plan to use Datopotamab Deruxtecan for HR+/HER2- MBC?
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared a post on X:
“Dato-DXd is now approved for treating patients with HR+/HER2- MBC after prior ET and chemo.
In TB01, Dato-DXd improved PFS over chemo in this population (6.9 vs 4.9 mo, HR 0.63, p<0.001).
How do you plan to use Dato-DXd for HR+/HER2- MBC, assuming immediate availability?”
Dr. Paolo Tarantino, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He completed a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023